Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=70 years of age or with ECOG PS of 2;~* advanced (stage IIIB or IV)non-small cell lung cancer;~* no prior systemic chemotherapy for advanced NSCLC or prior treatment with HER-axis targeted drugs.~Exclusion Criteria:~* active brain metastasis or spinal cord suppression;~* unstable systemic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).